April 19, 2017 Acad, Gov/Utilities Bio/Pharma/CRO PR/Corporate

Roche to present new data at AAN reinforcing efficacy and safety of newly FDA-approved OCREVUS™ (ocrelizumab) in two types of multiple sclerosis

Basel, 19 April 2017 Roche to present new data at AAN reinforcing efficacy and safety of newly FDA-approved OCREVUS™ (ocrelizumab) in two types of multiple sclerosis Data presentations will include platform sessions and posters across relapsing multiple sclerosis and primary progressive multiple sclerosis Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data on... Read more

April 19, 2017 Cell Analysis Tools M&A, Partnerships

Cellular Dynamics International Signs Distribution Deal with STEMCELL Technologies

Order Contact Careers Account Log In/Register Why CDI Partners & Providers Our Technology Cellular Therapy Drug Discovery Health & Nutrition Stem Cell Banking Products & Services iCell Products iCell Cardiomyocytes iCell Cardiomyocytes2 iCell Cardiac Progenitor Cells iCell Neurons iCell Astrocytes iCell DopaNeurons iCell GlutaNeurons iCell Hepatocytes 2.0 iCell Hepatoblasts iCell Skeletal Myoblasts iCell Endothelial Cells... Read more

April 18, 2017 Environ, Ag./Food & Bev Forensics & Security Lab Top-10 Product Launch

New X-ray Machine Handles Heavy Products in Washdown Environments

Thermo Scientific NextGuard Pro enables inspection/detection of up to 50 kg/110 lbs in IP65 plants MINNEAPOLIS, April 18, 2017 /PRNewswire/ — A new X-ray machine from Thermo Fisher Scientific engineered to handle heavy product weights of up to 50 kilograms/110 pounds in IP65 washdown environments will make its debut at Interpack 2017, May 4-10 in Düsseldorf,... Read more

April 18, 2017 Acad, Gov/Utilities Bio/Pharma/CRO

FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States

Basel, 18 April 2017 FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States First and only medicine approved to treat all forms of diabetic retinopathy Granted Priority Review Designation by the FDA based on analysis of results from a National Institutes of... Read more

April 18, 2017 Acad, Gov/Utilities Bio/Pharma/CRO

FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States

Basel, 18 April 2017 FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States First and only medicine approved to treat all forms of diabetic retinopathy Granted Priority Review Designation by the FDA based on analysis of results from a National Institutes of... Read more